Oryza Pharmaceuticals Inc.
18 drugs in NADAC|18 Generic,0 Brand
Oryza Pharmaceuticals Inc. lists 18 NDCs in the CMS NADAC file (18 generic, 0 brand), at an average NADAC of $0.13 per unit, with a week-over-week move of -4.9% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
18
18G / 0B
Avg Price / Unit
$0.1322
$0.05 – $0.30
Avg 7d Change
-4.89%
Across 18 drugs with changes
7d Activity
of 18 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
Metoprolol Succinate market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Central Nervous System Stimulant therapeutic class
Review the broader class where Oryza Pharmaceuticals Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Oryza Pharmaceuticals Inc. make?
Oryza Pharmaceuticals Inc. lists 18 NDCs in the CMS NADAC file — 18 generic and 0 brand products.
What is the average price of Oryza Pharmaceuticals Inc. drugs?
The average NADAC across Oryza Pharmaceuticals Inc.'s portfolio is $0.1322 per unit, ranging from $0.0476 to $0.2956.
What types of drugs does Oryza Pharmaceuticals Inc. make?
Oryza Pharmaceuticals Inc. makes drugs across 2 FDA pharmacologic classes. The most common by NDC count are Central Nervous System Stimulant (20), beta-Adrenergic Blocker (13).
Has Oryza Pharmaceuticals Inc. had any drug recalls?
No FDA enforcement recalls are matched to Oryza Pharmaceuticals Inc. in the openFDA feed.
How has Oryza Pharmaceuticals Inc.'s pricing changed recently?
Over the past 7 days, 2 Oryza Pharmaceuticals Inc. products rose and 16 fell, with a portfolio-wide average change of -4.9%.